AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] NeoGenomics, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.

Key details of the appointment include:

  • Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
  • She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
  • The appointment was publicly announced via press release on June 24, 2025

The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.

NeoGenomics ha annunciato un'espansione significativa del consiglio di amministrazione e una nuova nomina tramite un deposito Form 8-K. Il Consiglio di Amministrazione dell'azienda è passato da nove a dieci membri con la nomina di Marjorie C. Green come nuova direttrice, con effetto dal 19 giugno 2025.

I dettagli principali della nomina includono:

  • La signora Green rimarrà in carica fino all'assemblea annuale del 2026 degli azionisti o fino a dimissioni/rimozione
  • Riceverà una remunerazione in linea con il programma di compenso per direttori indipendenti già esistente, come indicato nella dichiarazione proxy del 2025
  • La nomina è stata resa pubblica tramite comunicato stampa il 24 giugno 2025

Il deposito, firmato dall'EVP e General Counsel Alicia C. Olivo, include le consuete dichiarazioni regolamentari e conferma che NeoGenomics non è classificata come società in crescita emergente. L'azienda è quotata al Nasdaq con il simbolo NEO.

NeoGenomics ha anunciado una expansión significativa de su junta directiva y un nombramiento a través de una presentación Form 8-K. La Junta Directiva de la compañía ha aumentado su tamaño de nueve a diez miembros con el nombramiento de Marjorie C. Green como nueva directora, efectivo a partir del 19 de junio de 2025.

Los detalles clave del nombramiento incluyen:

  • La Sra. Green servirá hasta la reunión anual de 2026 de accionistas o hasta su renuncia/remoción
  • Recibirá una compensación alineada con el programa de compensación para directores independientes existente de la compañía, según se divulga en la declaración proxy de 2025
  • El nombramiento fue anunciado públicamente mediante un comunicado de prensa el 24 de junio de 2025

La presentación, firmada por la EVP y Consejera General Alicia C. Olivo, incluye las divulgaciones regulatorias estándar y confirma que NeoGenomics no está clasificada como una empresa emergente en crecimiento. La compañía cotiza en el Nasdaq bajo el símbolo NEO.

NeoGenomicsëŠ� Form 8-K 제출ì� 통해 ì´ì‚¬íš� 규모 확대 ë°� ì‹ ê·œ ì´ì‚¬ 임명ì� 발표했습니다. 회사ì� ì´ì‚¬íšŒëŠ” 9명ì—ì„� 10ëª�으로 늘어났으ë©�, Marjorie C. Greenì� 2025ë…� 6ì›� 19ì¼ë¶€í„� ì‹ ìž„ ì´ì‚¬ë¡� 임명ë˜ì—ˆìŠµë‹ˆë‹�.

임명 주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • 그린 ì´ì‚¬ëŠ� 2026ë…� ì—°ë¡€ 주주ì´íšŒê¹Œì§€ ë˜ëŠ” 사임/í•´ìž„ 시까지 재ì§í•� 예정입니ë‹�
  • 2025ë…� 위임ìž� ë³´ê³ ì„œì— ê³µê°œë� 회사ì� 기존 ë…립 ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ë³´ìƒì� 받게 ë©ë‹ˆë‹�
  • ìž„ëª…ì€ 2025ë…� 6ì›� 24ì� ë³´ë„ìžë£Œë¥� 통해 공개 발표ë˜ì—ˆìŠµë‹ˆë‹�

EVP ê²� 법률 고문 Alicia C. Olivoê°€ 서명í•� 제출 서류ì—는 표준 규제 공시가 í¬í•¨ë˜ì–´ 있으ë©� NeoGenomicsê°€ ì‹ ìƒ ì„±ìž¥ 기업으로 분류ë˜ì§€ 않ìŒì� 확ì¸í•©ë‹ˆë‹�. 회사ëŠ� 나스ë‹� ì¦ê¶Œê±°ëž˜ì†Œì—ì„� NEOë¼ëŠ” 심볼ë¡� 거래ë˜ê³  있습니다.

NeoGenomics a annoncé une expansion significative de son conseil d'administration et une nomination dans un dépôt Form 8-K. Le conseil d'administration de la société est passé de neuf à dix membres avec la nomination de Marjorie C. Green en tant que nouvelle administratrice, effective à partir du 19 juin 2025.

Les détails clés de la nomination sont les suivants :

  • Mme Green exercera ses fonctions jusqu'à l'assemblée annuelle des actionnaires de 2026 ou jusqu'à sa démission/son retrait
  • Elle recevra une rémunération conforme au programme de rémunération des administrateurs indépendants existant de la société, tel que divulgué dans la déclaration de procuration de 2025
  • La nomination a été annoncée publiquement par communiqué de presse le 24 juin 2025

Le dépôt, signé par la EVP et conseillère juridique Alicia C. Olivo, comprend les divulgations réglementaires habituelles et confirme que NeoGenomics n'est pas classée comme une entreprise en croissance émergente. La société est cotée au Nasdaq sous le symbole NEO.

NeoGenomics hat eine bedeutende Erweiterung des Vorstands und eine Ernennung in einer Form 8-K Meldung bekannt gegeben. Der Vorstand des Unternehmens wurde von neun auf zehn Mitglieder erweitert, mit der Ernennung von Marjorie C. Green als neues Vorstandsmitglied, wirksam ab dem 19. Juni 2025.

Wichtige Details der Ernennung sind:

  • Frau Green wird bis zur Hauptversammlung 2026 der Aktionäre oder bis zu ihrem Rücktritt/Entfernung im Amt bleiben
  • Sie erhält eine Vergütung entsprechend dem bestehenden Vergütungsprogramm für unabhängige Direktoren, wie in der Proxy-Erklärung 2025 offengelegt
  • Die Ernennung wurde am 24. Juni 2025 öffentlich durch eine Pressemitteilung bekannt gegeben

Die Meldung, unterzeichnet von EVP und General Counsel Alicia C. Olivo, enthält die üblichen regulatorischen Offenlegungen und bestätigt, dass NeoGenomics nicht als wachsendes Jungunternehmen klassifiziert ist. Das Unternehmen ist an der Nasdaq unter dem Symbol NEO gelistet.

Positive
  • Board expansion and appointment of Marjorie C. Green as new director, increasing board diversity and oversight capabilities
Negative
  • None.

Insights

Analyzing...

NeoGenomics ha annunciato un'espansione significativa del consiglio di amministrazione e una nuova nomina tramite un deposito Form 8-K. Il Consiglio di Amministrazione dell'azienda è passato da nove a dieci membri con la nomina di Marjorie C. Green come nuova direttrice, con effetto dal 19 giugno 2025.

I dettagli principali della nomina includono:

  • La signora Green rimarrà in carica fino all'assemblea annuale del 2026 degli azionisti o fino a dimissioni/rimozione
  • Riceverà una remunerazione in linea con il programma di compenso per direttori indipendenti già esistente, come indicato nella dichiarazione proxy del 2025
  • La nomina è stata resa pubblica tramite comunicato stampa il 24 giugno 2025

Il deposito, firmato dall'EVP e General Counsel Alicia C. Olivo, include le consuete dichiarazioni regolamentari e conferma che NeoGenomics non è classificata come società in crescita emergente. L'azienda è quotata al Nasdaq con il simbolo NEO.

NeoGenomics ha anunciado una expansión significativa de su junta directiva y un nombramiento a través de una presentación Form 8-K. La Junta Directiva de la compañía ha aumentado su tamaño de nueve a diez miembros con el nombramiento de Marjorie C. Green como nueva directora, efectivo a partir del 19 de junio de 2025.

Los detalles clave del nombramiento incluyen:

  • La Sra. Green servirá hasta la reunión anual de 2026 de accionistas o hasta su renuncia/remoción
  • Recibirá una compensación alineada con el programa de compensación para directores independientes existente de la compañía, según se divulga en la declaración proxy de 2025
  • El nombramiento fue anunciado públicamente mediante un comunicado de prensa el 24 de junio de 2025

La presentación, firmada por la EVP y Consejera General Alicia C. Olivo, incluye las divulgaciones regulatorias estándar y confirma que NeoGenomics no está clasificada como una empresa emergente en crecimiento. La compañía cotiza en el Nasdaq bajo el símbolo NEO.

NeoGenomicsëŠ� Form 8-K 제출ì� 통해 ì´ì‚¬íš� 규모 확대 ë°� ì‹ ê·œ ì´ì‚¬ 임명ì� 발표했습니다. 회사ì� ì´ì‚¬íšŒëŠ” 9명ì—ì„� 10ëª�으로 늘어났으ë©�, Marjorie C. Greenì� 2025ë…� 6ì›� 19ì¼ë¶€í„� ì‹ ìž„ ì´ì‚¬ë¡� 임명ë˜ì—ˆìŠµë‹ˆë‹�.

임명 주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • 그린 ì´ì‚¬ëŠ� 2026ë…� ì—°ë¡€ 주주ì´íšŒê¹Œì§€ ë˜ëŠ” 사임/í•´ìž„ 시까지 재ì§í•� 예정입니ë‹�
  • 2025ë…� 위임ìž� ë³´ê³ ì„œì— ê³µê°œë� 회사ì� 기존 ë…립 ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ë³´ìƒì� 받게 ë©ë‹ˆë‹�
  • ìž„ëª…ì€ 2025ë…� 6ì›� 24ì� ë³´ë„ìžë£Œë¥� 통해 공개 발표ë˜ì—ˆìŠµë‹ˆë‹�

EVP ê²� 법률 고문 Alicia C. Olivoê°€ 서명í•� 제출 서류ì—는 표준 규제 공시가 í¬í•¨ë˜ì–´ 있으ë©� NeoGenomicsê°€ ì‹ ìƒ ì„±ìž¥ 기업으로 분류ë˜ì§€ 않ìŒì� 확ì¸í•©ë‹ˆë‹�. 회사ëŠ� 나스ë‹� ì¦ê¶Œê±°ëž˜ì†Œì—ì„� NEOë¼ëŠ” 심볼ë¡� 거래ë˜ê³  있습니다.

NeoGenomics a annoncé une expansion significative de son conseil d'administration et une nomination dans un dépôt Form 8-K. Le conseil d'administration de la société est passé de neuf à dix membres avec la nomination de Marjorie C. Green en tant que nouvelle administratrice, effective à partir du 19 juin 2025.

Les détails clés de la nomination sont les suivants :

  • Mme Green exercera ses fonctions jusqu'à l'assemblée annuelle des actionnaires de 2026 ou jusqu'à sa démission/son retrait
  • Elle recevra une rémunération conforme au programme de rémunération des administrateurs indépendants existant de la société, tel que divulgué dans la déclaration de procuration de 2025
  • La nomination a été annoncée publiquement par communiqué de presse le 24 juin 2025

Le dépôt, signé par la EVP et conseillère juridique Alicia C. Olivo, comprend les divulgations réglementaires habituelles et confirme que NeoGenomics n'est pas classée comme une entreprise en croissance émergente. La société est cotée au Nasdaq sous le symbole NEO.

NeoGenomics hat eine bedeutende Erweiterung des Vorstands und eine Ernennung in einer Form 8-K Meldung bekannt gegeben. Der Vorstand des Unternehmens wurde von neun auf zehn Mitglieder erweitert, mit der Ernennung von Marjorie C. Green als neues Vorstandsmitglied, wirksam ab dem 19. Juni 2025.

Wichtige Details der Ernennung sind:

  • Frau Green wird bis zur Hauptversammlung 2026 der Aktionäre oder bis zu ihrem Rücktritt/Entfernung im Amt bleiben
  • Sie erhält eine Vergütung entsprechend dem bestehenden Vergütungsprogramm für unabhängige Direktoren, wie in der Proxy-Erklärung 2025 offengelegt
  • Die Ernennung wurde am 24. Juni 2025 öffentlich durch eine Pressemitteilung bekannt gegeben

Die Meldung, unterzeichnet von EVP und General Counsel Alicia C. Olivo, enthält die üblichen regulatorischen Offenlegungen und bestätigt, dass NeoGenomics nicht als wachsendes Jungunternehmen klassifiziert ist. Das Unternehmen ist an der Nasdaq unter dem Symbol NEO gelistet.

0001077183FALSE00010771832025-06-192025-06-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 19, 2025
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:Trading Symbol(s):Name of each exchange on which registered:
Common Stock, par value $0.001 per shareNEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.
Ms. Green will serve as a member of the Board until the 2026 annual meeting of stockholders of the Company or until her resignation or removal and otherwise until her successor is elected. Ms. Green will receive compensation for their service as independent directors consistent with the Company's director compensation program previously disclosed in the Company's definitive proxy statement for its 2025 annual meeting of stockholders.
Item 7.01Regulation FD Disclosure
On June 24, 2025, the Company issued a press release regarding the foregoing, which is attached to the Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(a)
Not applicable
(b)
Not applicable
(c)
Not applicable
(d)
Exhibits.
99.1
Press Release of NeoGenomics, Inc. dated June 24, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
Date:June 24, 2025
By:
/s/ Alicia C. Olivo
Alicia C. Olivo
EVP, General Counsel & Business Development
and Corporate Secretary



FAQ

Who is the new board member appointed to NEO's Board of Directors in June 2025?

Marjorie C. Green was appointed as a new director to NeoGenomics' Board of Directors on June 19, 2025, increasing the board size from nine to ten members.

How long will Marjorie Green serve on NEO's Board of Directors?

Ms. Green will serve as a board member until the 2026 annual meeting of stockholders, or until her resignation or removal and otherwise until her successor is elected.

What compensation will NEO's new director Marjorie Green receive?

Ms. Green will receive compensation consistent with NeoGenomics' director compensation program for independent directors, as previously disclosed in the company's definitive proxy statement for its 2025 annual meeting of stockholders.

When did NEO announce the new board member appointment to the public?

NeoGenomics issued a press release regarding the board appointment on June 24, 2025, which was filed as Exhibit 99.1 to the 8-K.

What is the current size of NEO's Board of Directors after the new appointment?

Following the appointment of Marjorie C. Green, NeoGenomics' Board of Directors increased from nine to ten members.
Neogenomics Inc

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Latest SEC Filings

NEO Stock Data

902.15M
127.16M
1.23%
102.53%
2.71%
Diagnostics & Research
Services-testing Laboratories
United States
FORT MYERS